NCT00720941 · OUTCOME

Number of Participants With Adverse Events

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma · Source last updated 2025-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From study treatment start date till 28 days safety follow-up, assessed up to approximately 152 months

What was measured

The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.

Analysis population: Safety Population: all randomized participants who received at least one dose of study medication, according to the actual treatment received.

Groups in this outcome

Pazopanib 800 mg

Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Sunitinib 50 mg

Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Pazopanib 800 mg	554
Sunitinib 50 mg	548

Reported measurements

Adverse Events (AEs)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Pazopanib 800 mg	551	Not reported	Not reported	Not reported	Not reported
Sunitinib 50 mg	535	Not reported	Not reported	Not reported	Not reported

Serious Adverse Events (SAEs)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Pazopanib 800 mg	242	Not reported	Not reported	Not reported	Not reported
Sunitinib 50 mg	227	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
551
group Id
OG001
value
535
title
Adverse Events (AEs)
categories
measurements
group Id
OG000
value
242
group Id
OG001
value
227
title
Serious Adverse Events (SAEs)

denoms

counts
group Id
OG000
value
554
group Id
OG001
value
548
units
Participants

description

groups

description
Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
id
OG000
title
Pazopanib 800 mg
description
Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.
id
OG001
title
Sunitinib 50 mg

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Population: all randomized participants who received at least one dose of study medication, according to the actual treatment received.

reporting Status

POSTED

time Frame

From study treatment start date till 28 days safety follow-up, assessed up to approximately 152 months

title

Number of Participants With Adverse Events

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice